Methods for the identification and treatment of patients sensitive to anti IGF-1R inhibition therapy
US9110082B2 · kind B2 · utility
0Cited by
1References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 22, 2010 |
| Grant date | Aug 18, 2015 |
| Priority date | — |
| Expiry date | May 12, 2031 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/475
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to methods for treating a dalotuzumab responsive cancer, in a patient, comprising determining the expression level of liver kinase B1 (LKB1), in a cancer cell from the patient, and when said expression is determined to be lower than that of a control cell; administering, to said patient, a therapeutically effective amount of dalotuzumab. The invention also relates to methods for assessing neoplastic cells, selecting patients, selecting therapies as well as diagnostic methods.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.